In general, PD-1/PD-L1 checkpoint inhibitors “revive” T-cells (”exhausted” cytotoxic T-cells) within the tumor microenvironment by blocking the PD-1/PD-L1 interaction, which tumors use to inhibit a T-cell mediated immune response. This evidence concerns the gene CD274 and neoplasm.